Skip to main content
. Author manuscript; available in PMC: 2011 Nov 15.
Published in final edited form as: Clin Cancer Res. 2010 May 27;16(14):3639–3647. doi: 10.1158/1078-0432.CCR-09-3385

Fig 2.

Fig 2

Motesanib augments radiation response in tumor xenograft models. Mice bearing UM-SCC1 (A), SCC-1483 (B), or UMSCC-6 (C) tumors were treated with either motesanib or vehicle by oral gavage 5x weekly (■). Twice weekly radiation was also administered (*). Data points are expressed as mean tumor size (n=10/group) +/− SEM. Arrows represent days that tumors were harvested for immunohistochemistry (as presented in Figures 3 & 4).